title: Gene therapy of inherited retinal degenerations: prospects and challenges.
abstract: Because of its favorable anatomical and immunological characteristics, the eye has been at the forefront of translational gene therapy. Dozens of promising proofs of concept have been obtained in animal models of inherited retinal degenerations (IRDs), and some of them have been relayed to the clinic. The results from the first clinical trials for a congenital form of blindness have generated great interest and have demonstrated the safety and efficacy of intraocular administrations of viral vectors in humans. However, this progress has also generated new questions and posed challenges that need to be addressed to further expand the applicability of gene therapy in the eye, including safe delivery of viral vectors to the outer retina, treatment of dominant IRDs as well as of IRDs caused by mutations in large genes, and, finally, selection of the appropriate IRDs and patients to maximize the efficacy of gene transfer. This review summarizes the strategies that are currently being exploited to overcome these challenges and drive the clinical development of retinal gene therapy.
authors.affiliation: 1 Telethon Institute of Genetics and Medicine (TIGEM) , Pozzuoli, Naples 80078, Italy .
authors.forename: Ivana
authors.initials: I
authors.lastname: Trapani
authors.forename: Sandro
authors.initials: S
authors.lastname: Banfi
authors.forename: Francesca
authors.initials: F
authors.lastname: Simonelli
authors.forename: Enrico M
authors.initials: EM
authors.lastname: Surace
authors.forename: Alberto
authors.initials: A
authors.lastname: Auricchio
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D012160:Retina / Q000378:metabolism / Q000473:pathology; D012162:Retinal Degeneration / Q000235:genetics / Q000628:therapy*; D012243:Rhodopsin / Q000235:genetics / Q000378:metabolism; D014161:Transduction, Genetic
chemical_list: D012243:Rhodopsin